Treatment of cognitive impairment using a selective dopamine d1 receptor agonist
CA 2501781 A1 · Owner: Kusmierek, Jacques · Inventors: Kusmierek, Jacques
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods of using DAS-431 under conditions where it is administered at a dose that results in improved cognitive performance but without significant side effects are provided. Symptoms can be ameliorated during the period of treatment and, frequently, for substantially longer periods thereafter. In addition, the DAS-431 is provided at a level which does not negatively affect responsiveness to subsequent doses of DAS-431. Few adverse effects are observed, and the treatments can result in long term relief so as to avoid , frequent repetitive treatment.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 22, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 22, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 22, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.